About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Avastinís Future in FDAís Hands

by Savitha C Muppala on March 4, 2011 at 3:31 PM
Font : A-A+

 Avastinís Future in FDAís Hands

Avastin, the wonder drug which has been the last resort for many women suffering metastatic breast cancer, risked being disapproved by the FDA last December. Obviously, this is not good news for many advance-stage breast cancer patients.

Nearly 17,500 women rely on Avastin, an advanced stage breast cancer drug that helps reduce blood flow to tumors , thus slowing their growth, and even completely wiping out the tumors in some cases. Therefore, the drug helps women survive much longer.

Advertisement

Avastin is expensive and patients need to spend more than $90,000 a year on treatment.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
Obesity in Teens Make Inroads into Early Atrial Fibrillation
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Selfie Addiction Calculator Nutam (400mg) (Piracetam) Indian Medical Journals Blood - Sugar Chart Loram (2 mg) (Lorazepam) Sinopril (2mg) (Lacidipine) Pregnancy Confirmation Calculator Iron Intake Calculator Blood Donation - Recipients Diaphragmatic Hernia
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Avastinís Future in FDAís Hands Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests